Evidence map›Paper›PMID 34290609›Full record

ArticleFrontiers in pharmacology2021

Prediction of Srebp-1 as a Key Target of Qing Gan San Against MAFLD in Rats via RNA-Sequencing Profile Analysis.

Bendong Yang, Jingyue Sun, Shufei Liang, Peixuan Wu, Rui Lv, Yanping He, Deqi Li, Wenlong Sun, Xinhua Song

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Attenuating effect ofFrontiers in pharmacology · 2023
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Bendong YangSchool of Life Sciences, Shandong University of Technology, Zibo, China.
Jingyue SunKey Laboratory of Novel Food Resources Processing, Ministry of Agriculture and Rural Affairs/Key Laboratory of Agro-Products Processing Technology of Shandong Province/Institute of Agro-Food Science and Technology, Shandong Academy of Agricultural Sciences, Jinan, China.
Shufei LiangSchool of Life Sciences, Shandong University of Technology, Zibo, China.
Peixuan WuSchool of Life Sciences, Shandong University of Technology, Zibo, China.
Rui LvSchool of Life Sciences, Shandong University of Technology, Zibo, China.
Yanping HeSchool of Life Sciences, Shandong University of Technology, Zibo, China.
Deqi LiSchool of Life Sciences, Shandong University of Technology, Zibo, China.
Wenlong SunSchool of Life Sciences, Shandong University of Technology, Zibo, China.
Xinhua SongSchool of Life Sciences, Shandong University of Technology, Zibo, China.
Shandong University of Technology · CNMinistry of Agriculture and Rural Affairs · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolism-associated fatty liver disease (MAFLD) is the most common chronic liver disease worldwide, and the use of traditional Chinese medicines (TCMs) to treat this disease has attracted increasing attention. The Qing Gan San (QGS) formula comprises

Indexed as

metabolism-associated fatty liver diseaseQing Gan SanRNA sequencingSREBP-1traditional Chinese medicines

Identifiers

PMID34290609
PMCPMC8289482
OpenAlexW3186556157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.